Astrazeneca (AZN)

 

Latest News

AZ and MSD rapidly advance Lynparza in Japan

AstraZeneca and Merck & Co - known as MSD outside the US and Canada - have submitted a new drug application to Jap...

AZ diabetes medicine gets FDA approval

AstraZeneca's easy-to-use injectable medicine for patients with type-2 diabetes has been approved by the US Food and Dru...

AZ and MSD rapidly advance Lynparza in Japan

RNS Number: 2987U AstraZeneca PLC 23 October 2017 23 October 2017 07:00 BST ASTRAZENECA AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN WITH A SECOND REGULATORY SUBMISSION Potential to offer a new treatment option for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer AstraZeneca and Merck &...

US FDA approves Bydureon BCise for type-2 diabetes

RNS Number: 2668U AstraZeneca PLC 23 October 2017 23 October 2017 07:00 BST US FDA APPROVES NEW EASY-TO-USE, ONCE-WEEKLY BYDUREON BCISE INJECTABLE MEDICINE FOR PATIENTS WITH TYPE-2 DIABETES New formulation of once-weekly exenatide in an improved device provides significant HbA1c reduction with added benefit o...

All News

DateHeadlineSource
23-10-17AZ and MSD rapidly advance Lynparza in JapanStockMarketWire
23-10-17AZ diabetes medicine gets FDA approval StockMarketWire
23-10-17AZ and MSD rapidly advance Lynparza in JapanRNS
23-10-17US FDA approves Bydureon BCise for type-2 diabetesRNS
18-10-17FDA priority review for Lynparza in breast cancer, says AZStockMarketWire
18-10-17FDA Priority Review for Lynparza in breast cancerRNS
17-10-17AZ lung cancer drug granted priority review statusStockMarketWire
17-10-17FDA accepts sBLA file for Imfinzi; priority reviewRNS
16-10-17Broker Forecast - Credit Suisse issues a broker note on AstraZeneca PLCStockMarketWire
16-10-17Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLCStockMarketWire
11-10-17A debt warning and short selling Interactive Investor
09-10-17Broker Forecast - HSBC issues a broker note on AstraZeneca PLCStockMarketWire
09-10-17AZN cancer drug granted breakthrough therapy designation StockMarketWire
09-10-17FDA grants Tagrisso BTD for 1st-line EGFR nsclcRNS
02-10-17Total Voting RightsRNS
26-09-17Director/PDMR ShareholdingRNS
18-09-17Neil Woodford's trades in August 2017Interactive Investor
14-09-17Be patient with Neil Woodford Interactive Investor
14-09-17Aspen acquires remaining rights to AZ anaestheticsStockMarketWire
14-09-17Broker Forecast - Liberum Capital issues a broker note on AstraZeneca PLCStockMarketWire
14-09-17Aspen acquires remaining rights to AZ anaestheticsRNS
13-09-17Broker Forecast - JP Morgan Cazenove issues a broker note on AstraZeneca PLCStockMarketWire
11-09-17Stocks climb higher by the closeStockMarketWire
11-09-17Petra slumps as Provident ralliesStockMarketWire
11-09-17Broker Forecast - Bryan Garnier issues a broker note on AstraZeneca PLCStockMarketWire
11-09-17Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLCStockMarketWire
11-09-17Petra plummets on export block by Tanzanian authoritiesStockMarketWire
11-09-17Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLCStockMarketWire
11-09-17Tagrisso potential standard of care in lung cancerRNS
11-09-17IMFINZI superior PFS in Stage III lung cancerRNS
07-09-17Euro strong on European growth upgradeStockMarketWire
07-09-17Most-traded investments in August 2017Interactive Investor
07-09-17AZN trials placed on hold by FDAStockMarketWire
07-09-17Celgene and AZ update on Fusion trial programmeRNS
07-09-17Here's Neil Woodford's apology for dire performanceMoney Observer
07-09-17Shell and BP boost FTSEStockMarketWire
07-09-17Go-⁠Ahead operating profits fall as miners weakenStockMarketWire
07-09-17AZ reports positive study and trial results StockMarketWire
07-09-17AZ Duaklir improves lung function in COPD patientsRNS
07-09-17AZ tezepelumab cuts exacerbations in severe asthmaRNS

RSS feeds

  • Editorial news feed for LSE:AZN Editorial
  • Regulatory news feed for LSE:AZN Regulatory